Santarus Inc (SNTS)

[mlkrborn]

SNTS $3.16 on letter to file refusal? Its partner now 0.15 euro in europe..
Shares of partners Santarus Inc. (SNTS 3.18, -0.01, -0.21%) and Netherlands-based Pharming Group N.V. (NL:PHARM 0.15, -0.04, -18.62%) took a hit Monday on news that U.S. regulators have refused to accept their market application for the drug Rhucin due to insufficient data.

The companies are seeking to have Rhucin approved to treat the rare condition hereditary angioedema. Santarus and Pharming intend to meet regulators to discuss what will be needed to re-file the application.

Pharming shares sank almost 20% to 15 cents, while Santarus shares dipped 8% to $2.99.